

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (Original) A method for treating an inflammatory disease, disorder or cancer in a patient ~~of reducing a dosage size of an at least one NSAID in the treatment of a patient in need of an NSAID therapy, comprising:~~

~~simultaneous or step-wise administering of curcumin and said at least one NSAID to the patient, the curcumin being in an amount sufficient to reduce the NSAID concentration needed while maintaining the same therapeutic effect as compared to administering the NSAID alone,~~

wherein the NSAID is selected from the group consisting of ketorolac, nabumetone, salsalate, diclofenac, indomethacin, nabumetone, phenylbutazone, oxyphenbutazone, dipyrone, ramifenazone, tenoxicam, valdecoxib, parecoxib, etoricoxib, celecoxib, sulindac, sulindac sulfide, exisulind, ibuprofen, naproxen, naproxen sodium, rofecoxib, nimesulide, aspirin, tolmetin, fenoprofen, flurbiprofen, loxoprofen, vedaprofen, meclofenamic acid, meclofenamate sodium, tolfenamic acid, acetaminophen, flunixin, piroxicam, oxaprozin, meloxicam, ketoprofen, etodolac and diflunisal, or a salt or prodrug thereof.

2. (Cancelled)

3. (Currently Amended) The method according to claim 1 [[2]], wherein said the drug is selected from the group consisting of celecoxib, nimesulide, sulindac and [[or]] sulindac sulfide, or derivatives, analogues, salts or prodrugs thereof.

4. (Currently Amended) The method according to claim 1 [[2]], wherein said drug is not celecoxib or derivatives, analogues, salts or prodrugs thereof.

5. (Currently Amended) The method according to claim 1, wherein said curcumin is a curcumin analogue or derivative selected from the group consisting of demethoxycurcumin and bisdemethoxycurcumin.

6-8. (Cancelled)

9. (Previously Presented) The method according to claim 6, wherein said curcumin and said NSAID are administered not within the same formulation.

10. (Previously Presented) The method according to claim 6 wherein said NSAID is celecoxib, nimesulide, sulindac or sulindac sulfide or derivatives, analogues, salts or prodrugs thereof.

11. (Previously Presented) The method according to claim 6, wherein said NSAID is a drug other than celecoxib, or a drug other than sulindac, or a drug other than sulindac sulfide or derivatives, analogues, salts or prodrugs thereof.

12. (Currently Amended) A method for inhibiting cancer cell growth, comprising: contacting cancer cells with an effective amount of a formulation comprising curcumin and at least one NSAID selected from the group consisting of ketorolac, nabumetone, salsalate, diclofenac, indomethacin, nabumetone, phenylbutazone, oxyphenbutazone, dipyrone, ramifenazone, tenoxicam, valdecoxib, parecoxib, etoricoxib, celecoxib, sulindac, sulindac sulfide, exisulind, ibuprofen, naproxen, naproxen sodium, rofecoxib, nimesulide, aspirin, tolmetin, fenoprofen, flurbiprofen, loxoprofen, vedaprofen, meclofenamic acid, meclofenamate sodium, tolfenamic acid, acetaminophen, flunixin, piroxicam, oxaprozin, meloxicam, ketoprofen, etodolac and diflunisal, or a salt or prodrug thereof.

13. (Original) The method according to claim 12, wherein said cells are contacted with a single formulation comprising both curcumin and at least one NSAID.

14. (Currently Amended) The method according to claim 12, wherein said cells are contacted with a formulation comprising containing curcumin, followed by contacting with a second formulation containing said at least one NSAID.

15. (Original) The method according to claim 12 wherein said cells are contacted with a formulation containing said at least one NSAID, followed by contacting with a second formulation containing curcumin.

16-19. (Cancelled)

20. (Currently Amended) The method composition according to claim 1 [[19]], wherein said cancer is selected from leukemia, carcinomas, sarcomas, cancers of the brain, breast, cervix, colorectal, colon, head and neck, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus and Medulloblastoma.

21. (Currently Amended) The method composition according to claim 20, wherein said cancer is colorectal or colon cancer.

22. (Cancelled)

23. (Currently Amended) The method pharmaceutical composition according to claim 1 [[22]], wherein said inflammatory disease or disorder is selected from the group consisting of arthritis, rheumatoid arthritis (RA), spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, acne vulgaris, acute respiratory distress syndrome, Addison's disease, allergic rhinitis, allergic intraocular inflammatory diseases, ANCA-associated small-vessel vasculitis, atherosclerosis, atopic dermatitis, autoimmune hemolytic anemia, autoimmune hepatitis, Behcet's disease, Bell's palsy, cerebral ischemia, Cogan's syndrome, dermatomyositis and psoriatic arthritis.

24. (Currently Amended) The method pharmaceutical composition according to claim 23, wherein said inflammatory disease or disorder is arthritis.

25. (Currently Amended) The method according to composition of claim 1 [[20]], further comprising administering one or more additional active ingredients, selected from antibiotics, conventional anti-cancer[[,]] and anti-inflammatory agents and other agents suitable for combination therapy.

26-31. (Cancelled)

32. (Currently amended) A combination of two pharmaceutical compositions,
including comprising:

a first composition comprising an effective amount of at least one NSAID drug
selected from the group consisting of ketorolac, nabumetone, salsalate, diclofenac,
indomethacin, nabumetone, phenylbutazone, oxyphenbutazone, dipyrone, ramifenazone,
tenoxicam, valdecoxib, parecoxib, etoricoxib, celecoxib, sulindac, sulindac sulfide,
exisulind, ibuprofen, naproxen, naproxen sodium, rofecoxib, nimesulide, aspirin, tolmetin,
fenoprofen, flurbiprofen, loxoprofen, vedaprofen, meclofenamic acid, meclofenamate
sodium, tolfenamic acid, acetaminophen, flunixin, piroxicam, oxaprozin, meloxicam,
ketoprofen, etodolac and diflunisal, or a salt or prodrug thereof;[.,]] and

a second composition comprising an effective amount of curcumin, the combination
is intended for administering to a subject for treatment of cancer or inflammation, in which
treatment

wherein said second composition is administered after administering said first
composition.

33-45. (Cancelled)